XML 34 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Related Party Transactions
 6 Months Ended
Jun. 30, 2021
Related Party Transactions [Abstract]  
Related Party Transactions

9.

Related Party Transactions

Astellas is an equity investor in the Company and is considered a related party. The Company recorded revenue related to collaboration agreements with Astellas of $2.6 million and $4.8 million for the three months ended June 30, 2021 and 2020, and $6.3 million and $9.5 million for the six months ended June 30, 2021 and 2020, respectively. The Company also recorded drug product revenue from Astellas of $(2.0) million and $8.2 million for the three months ended June 30, 2021 and 2020, and $2.1 million and $8.2 million for the six months ended June 30, 2021 and 2020, respectively. See Note 2, Collaboration Agreements and Revenues, for details.

The Company’s expense related to collaboration agreements with Astellas was immaterial for each of the three and six months ended June 30, 2021 and 2020.

As of June 30, 2021 and December 31, 2020, accounts receivable from Astellas were $2.6 million and $4.1 million, respectively.

As of June 30, 2021 and December 31, 2020, total deferred revenue from Astellas was $20.1 million and $7.5 million, respectively.

As of June 30, 2021, the amount due to Astellas was immaterial. As of December 31, 2020, amount due to Astellas was $1.1 million.

Falikang, an entity jointly owned by FibroGen Beijing and AstraZeneca is an unconsolidated VIE accounted for as an equity method investment, and considered as a related party to the Company. FibroGen Beijing owns 51.1% of Falikang’s equity. See Note 3, Variable Interest Entity, for details.

For the three and six months ended June 30, 2021, the net product revenue from Falikang was $11.8 million and $22.2 million, respectively. See Note 2, Collaboration Agreements and Revenues, for details.

For the three and six months ended June 30, 2021, the investment income in Falikang was $0.6 million and $0.3 million, respectively. As of June 30, 2021 and December 31, 2020, the Company’s equity method investment in Falikang was $3.1 million and $2.7 million, respectively. See Note 3, Variable Interest Entity, for details.

As of June 30, 2021, accounts receivable, net, from Falikang was of $10.8 million.

As of June 30, 2021, there was no miscellaneous receivables from Falikang. As of December 31, 2020, prepaid expenses and other current assets included miscellaneous receivables from Falikang of $0.9 million.